Journal
AMYOTROPHIC LATERAL SCLEROSIS
Volume 12, Issue 1, Pages 33-38Publisher
INFORMA HEALTHCARE
DOI: 10.3109/17482968.2010.531742
Keywords
Amyotrophic lateral sclerosis; motor neuron disease; neurophysiology; clinical trial; mixed effects model
Categories
Funding
- Australian Rotary Health Research Amyotrophic Lateral Sclerosis Fund
- National Health and Medical Research Council of Australia
- University of New South Wales BrainSciences
- Pfizer Biostatistics Collaboration of Australia
- Clive and Vera Ramaciotti Establishment grant
- Sylvia and Charles Viertel Charitable Foundation
- New South Wales Office of Science and Medicine Research
- Motor Neurone Disease Research Institute of Australia
Ask authors/readers for more resources
Our objective was to evaluate the neurophysiological index (NI) as a biomarker for amyotrophic lateral sclerosis (ALS) and to assess the validity of linear mixed effects models for describing longitudinal changes. Functional assessment and nerve conduction studies were undertaken in 58 ALS patients. Neurophysiological data were collected on four occasions over 12 weeks (baseline, weeks 4, 8 and 12). The NI was calculated for the abductor digiti minimi and ulnar nerve at the wrist. NI declined at a rate of 0.04 per week (S. E. 0.006, p < 0.0001). Patients with bulbar-onset disease had 0.88 greater NI than patients with upper limb-onset disease over the follow-up period (S. E. 0.39, p. - 0.03). There were no differences in the rates of decline among patients with different disease phenotypes. Rates of change in NI and functional impairment were weakly correlated (Spearman's rho = 0.29, p = 0.03). Linear mixed effects models were appropriate for detailing the longitudinal changes in NI. The present findings support incorporation of NI as an outcome measure for ALS clinical trials conducted over short time periods.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available